Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ripretinib

FDA-approved product (tablet, oral), marketed as Qinlock.

Registered studies
19
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Ripretinib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Gastrointestinal stromal tumor
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other protein kinase inhibitors
FDA pharmacologic class
Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA49.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli37.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae21.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis54.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

19registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Ripretinib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.2 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ripretinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Resistance Profiling Using Functional Imaging and Next Generation Sequencing in Refractory Gastrointestinal Stomal Tumors (GIST)

    NCT07109024 · start 2025-09-01

    Registered record
    Registry ID
    NCT07109024
    Conditions
    Gastrointestinal Stromal Tumor (GIST)
    Interventions
    Generation of a comprehensive and single-lesion resistance profile
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2025-09-01
    Completion
    2031-03
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastrointestinal Stromal Tumor (GIST)
    InterventionGeneration of a comprehensive and single-lesion resistance profile
    PhaseNot recorded
    Registry statusNot yet recruiting

  • Ripretinib (QINLOCK®) According to Current SmPC

    NCT06619275 · start 2024-10-17

    Registered record
    Registry ID
    NCT06619275
    Conditions
    GIST - Gastrointestinal Stromal Tumor
    Interventions
    Ripretinib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2024-10-17
    Completion
    2025-09-15
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGIST - Gastrointestinal Stromal Tumor
    InterventionRipretinib
    PhaseNot recorded
    Registry statusCompleted

  • The Correlation Between Ripretinib Exposure and the Efficacy and Safety in Patients with Advanced GISTs

    NCT06431451 · start 2024-06-01

    Registered record
    Registry ID
    NCT06431451
    Conditions
    Gastrointestinal Stromal Tumors
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2024-06-01
    Completion
    2025-12
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastrointestinal Stromal Tumors
    InterventionNot recorded
    PhaseNot recorded
    Registry statusUnknown

  • Evaluate the Efficacy and Safety of Radiotherapy Combined With Ripretinib in the Treatment of Unresectable Advanced GIST

    NCT06507683 · start 2024-05-28

    Registered record
    Registry ID
    NCT06507683
    Conditions
    Gastrointestinal Stromal Tumors
    Interventions
    simultaneous integrated boost intensity-modulated radiation therapy combined with ripretinib
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2024-05-28
    Completion
    2027-07
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastrointestinal Stromal Tumors
    Interventionsimultaneous integrated boost intensity-modulated radiation therapy combined with ripretinib
    PhaseNot applicable
    Registry statusRecruiting

  • A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib

    NCT05734105 · start 2023-12-13

    Registered record
    Registry ID
    NCT05734105
    Conditions
    GIST
    Interventions
    Ripretinib; Sunitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2023-12-13
    Completion
    2028-12
    Enrolment
    54

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGIST
    InterventionRipretinib; Sunitinib
    PhasePhase 3
    Registry statusActive not recruiting

  • A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies

    NCT05957367 · start 2023-09-28

    Registered record
    Registry ID
    NCT05957367
    Conditions
    GIST
    Interventions
    Inlexisertib; Ripretinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2023-09-28
    Completion
    2029-03
    Enrolment
    94

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGIST
    InterventionInlexisertib; Ripretinib
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors

    NCT05489237 · start 2022-08-03

    Registered record
    Registry ID
    NCT05489237
    Conditions
    Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumor (GIST); Digestive System Disease; Gastrointestinal Diseases; Metastatic Cancer
    Interventions
    IDRX-42
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2022-08-03
    Completion
    2027-03-26
    Enrolment
    276

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastrointestinal Neoplasms; Gastrointestinal Stromal Tumor (GIST); Digestive System Disease; Gastrointestinal Diseases +1 more
    InterventionIDRX-42
    PhasePhase 1
    Registry statusActive not recruiting

  • A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)

    NCT05160168 · start 2022-01-03

    Registered record
    Registry ID
    NCT05160168
    Conditions
    Gastrointestinal Stromal Tumors (GIST); Neoplasms, Connective Tissue; Neoplasms, Connective and Soft Tissue; Neoplasms by Histologic Type; Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasm; Digestive System Disease; Gastrointestinal Diseases
    Interventions
    THE-630
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2022-01-03
    Completion
    2024-02-02
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastrointestinal Stromal Tumors (GIST); Neoplasms, Connective Tissue; Neoplasms, Connective and Soft Tissue; Neoplasms by Histologic Type +5 more
    InterventionTHE-630
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST)

    NCT05080621 · start 2021-11

    Registered record
    Registry ID
    NCT05080621
    Conditions
    Gastrointestinal Stromal Tumors
    Interventions
    Ripretinib; binimetinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Withdrawn
    Start
    2021-11
    Completion
    2027-05
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastrointestinal Stromal Tumors
    InterventionRipretinib; binimetinib
    PhasePhase 1 / Phase 2
    Registry statusWithdrawn

  • Ripretinib Combined With Surgery in Advanced GIST That Have Failed Imatinib Therapy: A Multicenter,Observational Study

    NCT05354388 · start 2021-10-01

    Registered record
    Registry ID
    NCT05354388
    Conditions
    Gastrointestinal Stromal Tumor(GIST)
    Interventions
    Resection surgery of gastrointestinal stromal tumor
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2021-10-01
    Completion
    2023-12-30
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastrointestinal Stromal Tumor(GIST)
    InterventionResection surgery of gastrointestinal stromal tumor
    PhaseNot recorded
    Registry statusUnknown

  • A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients with Advanced GIST

    NCT04530981 · start 2021-09-22

    Registered record
    Registry ID
    NCT04530981
    Conditions
    GIST - Gastrointestinal Stromal Tumor
    Interventions
    Ripretinib; Repaglinide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-09-22
    Completion
    2024-07-29
    Enrolment
    13

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGIST - Gastrointestinal Stromal Tumor
    InterventionRipretinib; Repaglinide
    PhasePhase 1
    Registry statusCompleted

  • Ripretinib Used for Resectable Metastatic GIST After Failure of Imatinib Therapy

    NCT05132738 · start 2021-08-01

    Registered record
    Registry ID
    NCT05132738
    Conditions
    Gastrointestinal Stromal Tumors
    Interventions
    Ripretinib treatment
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2021-08-01
    Completion
    2023-11-30
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastrointestinal Stromal Tumors
    InterventionRipretinib treatment
    PhaseNot applicable
    Registry statusUnknown

  • Ripretinib in Chinese Patients With Advanced GIST: a Real World Study

    NCT05697107 · start 2021-05-20

    Registered record
    Registry ID
    NCT05697107
    Conditions
    Gastrointestinal Stromal Tumors
    Interventions
    Ripretinib Oral Tablet
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2021-05-20
    Completion
    2023-12-30
    Enrolment
    308

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastrointestinal Stromal Tumors
    InterventionRipretinib Oral Tablet
    PhaseNot recorded
    Registry statusUnknown

  • A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib

    NCT04633122 · start 2020-11-25

    Registered record
    Registry ID
    NCT04633122
    Conditions
    Gastrointestinal Stromal Tumor(GIST)
    Interventions
    Ripretinib; Sunitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2020-11-25
    Completion
    2022-07-20
    Enrolment
    108

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastrointestinal Stromal Tumor(GIST)
    InterventionRipretinib; Sunitinib
    PhasePhase 2
    Registry statusCompleted

  • A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST)

    NCT04282980 · start 2020-04-23

    Registered record
    Registry ID
    NCT04282980
    Conditions
    Gastrointestinal Stromal Tumors
    Interventions
    DCC-2618
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2020-04-23
    Completion
    2022-08-23
    Enrolment
    39

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastrointestinal Stromal Tumors
    InterventionDCC-2618
    PhasePhase 2
    Registry statusCompleted